UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process

Transfusion (Philadelphia, Pa.), 2011-11, Vol.51 (11), p.2367-2376

2011

Volltextzugriff (PDF)

Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) and Cryoprecipitated AHF Contain Von Willebrand Factor with Comparable Binding to Collagen and Support Shear-Induced Platelet Thrombus Formation

Blood, 2023-11, Vol.142 (Supplement 1), p.4039-4039

2023

Volltextzugriff (PDF)

Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione

Transfusion (Philadelphia, Pa.), 2020-02, Vol.60 (2), p.358-366

2020

Volltextzugriff (PDF)

In vivo genotoxicity assessment of N‐(‐9 acridinyl)‐b‐alanine hydrochloride (S‐300) using a validated Pig‐a mutagenesis assay

Transfusion (Philadelphia, Pa.), 2024-06, Vol.64 (6), p.1097-1108

2024

Volltextzugriff (PDF)

P-43 Inactivation des pathogènes et qualité des CGR traités par amustaline

Transfusion clinique et biologique : journal de la Société française de transfusion sanguine, 2022-11, Vol.29 (4), p.361-361

2022

Volltextzugriff (PDF)

Amustaline‐glutathione pathogen‐reduced red blood cell concentrates for transfusion‐dependent thalassaemia

British journal of haematology, 2019-08, Vol.186 (4), p.625-636

2019

Volltextzugriff (PDF)

Prevalence of natural and acquired antibodies to amustaline/glutathione pathogen reduced red blood cells

Transfusion (Philadelphia, Pa.), 2020-10, Vol.60 (10), p.2389-2398

2020

Volltextzugriff (PDF)

Evaluation of amotosalen and UVA pathogen‐reduced apheresis platelets after 7‐day storage

Transfusion (Philadelphia, Pa.), 2022-08, Vol.62 (8), p.1619-1629

2022

Volltextzugriff (PDF)

Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates

Transfusion medicine and hemotherapy, 2011-01, Vol.38 (1), p.33-42

2011

Volltextzugriff (PDF)

Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC)

Blood, 2018-11, Vol.132 (Supplement 1), p.3812-3812

2018

Volltextzugriff (PDF)

Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment

Transfusion (Philadelphia, Pa.), 2011-10, Vol.51 (10), p.2208-2218

2011

Volltextzugriff (PDF)

Essais cliniques avec des globules rouges sécurisés par traitement amustaline/glutathion

Transfusion clinique et biologique : journal de la Société française de transfusion sanguine, 2019-09, Vol.26 (3), p.S45-S46

2019

Volltextzugriff (PDF)

Red blood cells treated with the amustaline (S‐303) pathogen reduction system: a transfusion study in cardiac surgery

Transfusion (Philadelphia, Pa.), 2018-04, Vol.58 (4), p.905-916

2018

Volltextzugriff (PDF)

Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post‐thaw storage at 1 to 6oC

Transfusion (Philadelphia, Pa.), 2017-04, Vol.57 (4), p.997-1006

2017

Volltextzugriff (PDF)

Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6 o C

Transfusion (Philadelphia, Pa.), 2017-04, Vol.57 (4), p.997-1006

2017

Volltextzugriff (PDF)

Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment

Transfusion (Philadelphia, Pa.), 2014-07, Vol.54 (7), p.1798-1807

2014

Volltextzugriff (PDF)

Caractérisation in vitro des concentrés plaquettaires traités par INTERCEPT et conservés pendant 7 jours

Transfusion clinique et biologique : journal de la Société française de transfusion sanguine, 2018-11, Vol.25 (4), p.341-342

2018

Volltextzugriff (PDF)

Cryoprécipité issu de plasma atténué pour les agents pathogènes par amotosalen

Transfusion clinique et biologique : journal de la Société française de transfusion sanguine, 2017-09, Vol.24 (3), p.296-296

2017

Volltextzugriff (PDF)

Plasma atténué pour les agents pathogènes par amotosalen conservé liquide

Transfusion clinique et biologique : journal de la Société française de transfusion sanguine, 2017-09, Vol.24 (3), p.368-368

2017

Volltextzugriff (PDF)

Conservation de globules rouges atténués pour les agents pathogènes

Transfusion clinique et biologique : journal de la Société française de transfusion sanguine, 2017-09, Vol.24 (3), p.334-334

2017

Volltextzugriff (PDF)

Progress towards an appropriate pathogen reduction technology for whole blood in Africa

ISBT science series, 2020-02, Vol.15 (1), p.151-163

2020

Volltextzugriff (PDF)

Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6o C

Transfusion (Philadelphia, Pa.), 2017-04, Vol.57 (4), p.997-1006

2017

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled, Dose-Escalation, Phase 1 Study of the Safety and Pharmacokinetics of Amphotericin B Inhalation Powder in Healthy Subjects

Blood, 2007-11, Vol.110 (11), p.4988-4988

2007

Volltextzugriff (PDF)

Disruption and Collaboration in Digital Journalism: Ambivalence of Social Responsibility and Political Economy Practices of Media Companies

Jurnal komunikasi, Malaysian journal of communication, 2021-01, Vol.37 (1), p.181-195

2021

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(34)
Tagungsberichte
(2)

Sprache

Englisch
(31)
Französisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Hematology
(11)
Erythrocytes
(6)
Humans
(6)
Male
(6)
Pathogens
(6)
Female
(5)
Glutathione
(5)
Transfusion
(5)
Adult
(3)
Aged
(3)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(3)
Animals
(3)
Antibodies
(3)
Biological And Medical Sciences
(3)
Health Risks
(3)
Heart Surgery
(3)
In Vivo Methods And Tests
(3)
Leukocytes
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial

Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process

Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) and Cryoprecipitated AHF Contain Von Willebrand Factor with Comparable Binding to Collagen and Support Shear-Induced Platelet Thrombus Formation

Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione

In vivo genotoxicity assessment of N‐(‐9 acridinyl)‐b‐alanine hydrochloride (S‐300) using a validated Pig‐a mutagenesis assay

P-43 Inactivation des pathogènes et qualité des CGR traités par amustaline

Amustaline‐glutathione pathogen‐reduced red blood cell concentrates for transfusion‐dependent thalassaemia

Prevalence of natural and acquired antibodies to amustaline/glutathione pathogen reduced red blood cells

Evaluation of amotosalen and UVA pathogen‐reduced apheresis platelets after 7‐day storage

Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates

Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC)

Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment

Essais cliniques avec des globules rouges sécurisés par traitement amustaline/glutathion

Red blood cells treated with the amustaline (S‐303) pathogen reduction system: a transfusion study in cardiac surgery

Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post‐thaw storage at 1 to 6oC

Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6 o C

Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment

Caractérisation in vitro des concentrés plaquettaires traités par INTERCEPT et conservés pendant 7 jours

Cryoprécipité issu de plasma atténué pour les agents pathogènes par amotosalen

Plasma atténué pour les agents pathogènes par amotosalen conservé liquide

Conservation de globules rouges atténués pour les agents pathogènes

Progress towards an appropriate pathogen reduction technology for whole blood in Africa

Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6o C

A Randomized, Placebo-Controlled, Dose-Escalation, Phase 1 Study of the Safety and Pharmacokinetics of Amphotericin B Inhalation Powder in Healthy Subjects

Disruption and Collaboration in Digital Journalism: Ambivalence of Social Responsibility and Political Economy Practices of Media Companies

Suchergebnisse filtern